[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flHA8LpPpE4XY2V0MglRyVtPMma8bBV4TudPNphcEv84":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":83,"rows":90},"Institut Bergonié",[4],119,false,28,5,247135,19,71,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Breast Cancer",24,{"name":18,"count":19},"Cancer",12,{"name":21,"count":22},"Prostate Cancer",10,{"name":24,"count":25},"Colorectal Cancer",9,{"name":27,"count":28},"Sarcoma",6,{"name":30,"count":9},"Lymphoma",{"name":32,"count":9},"Non Small Cell Lung Cancer",{"name":34,"count":35},"Soft Tissue Sarcoma Adult",4,[37,42,47,52,57,61,64,68,73,78],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04968106","Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)","2025-08-06","Doxorubicin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05888857","MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.","2026-03","MEDI5752",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04339218","Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","2026-08-27","Pembrolizumab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05346848","Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","2026-12","Association of darolutamide and EBRT",{"nctId":58,"briefTitle":59,"date":55,"intervention":60},"NCT03915678","Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors","Association atezolizumab + BDB001 + RT",{"nctId":62,"briefTitle":63,"date":55,"intervention":41},"NCT03805022","Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas",{"nctId":65,"briefTitle":66,"date":55,"intervention":67},"NCT05182164","Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas","Association of pembrolizumab + cabozantinib",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04258137","Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study","2026-12-01","Liquid biopsy",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04874311","Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma","2027-01","Bintrafusp alfa",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT03978039","National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group","2030-12-31","Chemotherapy",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,141,166,184,202,220,238,260,278,306,324,342,360,382,405,423,462,483,501,519,547,565,583,610,628,666,713,753,775,801,819,848,866,892,916,942,960,986,1004,1029,1055,1080,1098,1116,1134,1152,1177,1195,1221,1239,1264,1293,1311,1329,1347,1374,1392,1432,1450,1468,1486,1504,1522,1540,1558,1576,1594,1612,1639,1657,1683,1701,1719,1737,1766,1784,1810,1828,1853,1879,1906,1924,1942,1960,1984,2014,2040,2064,2092,2110,2128,2146,2164,2182,2205,2231],{"intervention":41,"totalTrials":92,"cells":93},3,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":123,"PHASE4":137,"NA":139},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":122,"soonestReadout":40},[101,112],{"nctId":38,"briefTitle":39,"status":102,"phases":103,"primaryCompletion":40,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"ACTIVE_NOT_RECRUITING",[86],"2028-04","2022-12-07",66,[108],"Resectable Sarcoma",[41,110,111],"Ifosfamide","INCMGA00012",{"nctId":74,"briefTitle":75,"status":113,"phases":114,"primaryCompletion":76,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"RECRUITING",[86],"2027-07","2022-03-01",80,[119,120],"Advanced Soft-tissue Sarcoma","Metastatic Soft-tissue Sarcoma",[77,41],2,{"trials":124,"activeCount":136,"soonestReadout":55},[125],{"nctId":62,"briefTitle":63,"status":113,"phases":126,"primaryCompletion":55,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":133},[87],"2028-12","2019-02-14",351,[131,132],"Non-metastatic Soft-tissue Sarcoma","Resectable",[41,134,41,134,135],"Ifosfamide or dacarbazine","At the discretion of the investigator",1,{"trials":138,"activeCount":96},[],{"trials":140,"activeCount":96},[],{"intervention":51,"totalTrials":136,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":162,"NA":164},{"trials":144,"activeCount":96},[],{"trials":146,"activeCount":96},[],{"trials":148,"activeCount":96},[],{"trials":150,"activeCount":136,"soonestReadout":50},[151],{"nctId":48,"briefTitle":49,"status":113,"phases":152,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},[87],"2028-08-27","2020-08-28",214,[157,158],"Lung Adenocarcinoma","Cryotherapy Effect",[51,160,161],"Pemetrexed","Carboplatin",{"trials":163,"activeCount":96},[],{"trials":165,"activeCount":96},[],{"intervention":160,"totalTrials":136,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":180,"NA":182},{"trials":169,"activeCount":96},[],{"trials":171,"activeCount":96},[],{"trials":173,"activeCount":96},[],{"trials":175,"activeCount":136,"soonestReadout":50},[176],{"nctId":48,"briefTitle":49,"status":113,"phases":177,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":178,"interventions":179},[87],[157,158],[51,160,161],{"trials":181,"activeCount":96},[],{"trials":183,"activeCount":96},[],{"intervention":161,"totalTrials":136,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":198,"NA":200},{"trials":187,"activeCount":96},[],{"trials":189,"activeCount":96},[],{"trials":191,"activeCount":96},[],{"trials":193,"activeCount":136,"soonestReadout":50},[194],{"nctId":48,"briefTitle":49,"status":113,"phases":195,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":196,"interventions":197},[87],[157,158],[51,160,161],{"trials":199,"activeCount":96},[],{"trials":201,"activeCount":96},[],{"intervention":134,"totalTrials":136,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":216,"NA":218},{"trials":205,"activeCount":96},[],{"trials":207,"activeCount":96},[],{"trials":209,"activeCount":96},[],{"trials":211,"activeCount":136,"soonestReadout":55},[212],{"nctId":62,"briefTitle":63,"status":113,"phases":213,"primaryCompletion":55,"completion":127,"start":128,"enrollment":129,"conditions":214,"interventions":215},[87],[131,132],[41,134,41,134,135],{"trials":217,"activeCount":96},[],{"trials":219,"activeCount":96},[],{"intervention":135,"totalTrials":136,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":96},[],{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":96},[],{"trials":229,"activeCount":136,"soonestReadout":55},[230],{"nctId":62,"briefTitle":63,"status":113,"phases":231,"primaryCompletion":55,"completion":127,"start":128,"enrollment":129,"conditions":232,"interventions":233},[87],[131,132],[41,134,41,134,135],{"trials":235,"activeCount":96},[],{"trials":237,"activeCount":96},[],{"intervention":56,"totalTrials":136,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":241,"activeCount":96},[],{"trials":243,"activeCount":96},[],{"trials":245,"activeCount":136,"soonestReadout":55},[246],{"nctId":53,"briefTitle":54,"status":113,"phases":247,"primaryCompletion":55,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":252},[86],"2030-02","2023-02-24",62,[21],[56,253],"Association of ADT and EBRT",{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":96},[],{"trials":259,"activeCount":96},[],{"intervention":253,"totalTrials":136,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":263,"activeCount":96},[],{"trials":265,"activeCount":96},[],{"trials":267,"activeCount":136,"soonestReadout":55},[268],{"nctId":53,"briefTitle":54,"status":113,"phases":269,"primaryCompletion":55,"completion":248,"start":249,"enrollment":250,"conditions":270,"interventions":271},[86],[21],[56,253],{"trials":273,"activeCount":96},[],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":96},[],{"intervention":60,"totalTrials":136,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":300,"PHASE4":302,"NA":304},{"trials":281,"activeCount":96},[],{"trials":283,"activeCount":96},[],{"trials":285,"activeCount":136,"soonestReadout":55},[286],{"nctId":58,"briefTitle":59,"status":113,"phases":287,"primaryCompletion":55,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":298},[86],"2027-12","2021-03-31",247,[292,293,294,32,295,296,297],"Solid Tumor, Adult","Pancreatic Cancer","Virus-associated Tumors","Melanoma","Bladder Cancer","Triple Negative Breast Cancer",[60,299,299,60,60,60],"Association atezolizumab + BDB001+ RT",{"trials":301,"activeCount":96},[],{"trials":303,"activeCount":96},[],{"trials":305,"activeCount":96},[],{"intervention":299,"totalTrials":136,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":309,"activeCount":96},[],{"trials":311,"activeCount":96},[],{"trials":313,"activeCount":136,"soonestReadout":55},[314],{"nctId":58,"briefTitle":59,"status":113,"phases":315,"primaryCompletion":55,"completion":288,"start":289,"enrollment":290,"conditions":316,"interventions":317},[86],[292,293,294,32,295,296,297],[60,299,299,60,60,60],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":96},[],{"trials":323,"activeCount":96},[],{"intervention":110,"totalTrials":136,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":327,"activeCount":96},[],{"trials":329,"activeCount":96},[],{"trials":331,"activeCount":136,"soonestReadout":40},[332],{"nctId":38,"briefTitle":39,"status":102,"phases":333,"primaryCompletion":40,"completion":104,"start":105,"enrollment":106,"conditions":334,"interventions":335},[86],[108],[41,110,111],{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":96},[],{"trials":341,"activeCount":96},[],{"intervention":111,"totalTrials":136,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":354,"PHASE4":356,"NA":358},{"trials":345,"activeCount":96},[],{"trials":347,"activeCount":96},[],{"trials":349,"activeCount":136,"soonestReadout":40},[350],{"nctId":38,"briefTitle":39,"status":102,"phases":351,"primaryCompletion":40,"completion":104,"start":105,"enrollment":106,"conditions":352,"interventions":353},[86],[108],[41,110,111],{"trials":355,"activeCount":96},[],{"trials":357,"activeCount":96},[],{"trials":359,"activeCount":96},[],{"intervention":67,"totalTrials":136,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":363,"activeCount":96},[],{"trials":365,"activeCount":96},[],{"trials":367,"activeCount":136,"soonestReadout":55},[368],{"nctId":65,"briefTitle":66,"status":113,"phases":369,"primaryCompletion":55,"completion":288,"start":370,"enrollment":6,"conditions":371,"interventions":375},[86],"2022-04-25",[34,119,372,373,374],"Ewing Sarcoma","Osteosarcoma","Undifferentiated Pleomorphic Sarcoma",[67],{"trials":377,"activeCount":96},[],{"trials":379,"activeCount":96},[],{"trials":381,"activeCount":96},[],{"intervention":46,"totalTrials":136,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":385,"activeCount":96},[],{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":136,"soonestReadout":45},[390],{"nctId":43,"briefTitle":44,"status":391,"phases":392,"primaryCompletion":45,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":398},"NOT_YET_RECRUITING",[86],"2028-09","2025-09",102,[397],"Advanced Solid Tumor",[46],{"trials":400,"activeCount":96},[],{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":96},[],{"intervention":77,"totalTrials":136,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":96},[],{"trials":412,"activeCount":136,"soonestReadout":76},[413],{"nctId":74,"briefTitle":75,"status":113,"phases":414,"primaryCompletion":76,"completion":115,"start":116,"enrollment":117,"conditions":415,"interventions":416},[86],[119,120],[77,41],{"trials":418,"activeCount":96},[],{"trials":420,"activeCount":96},[],{"trials":422,"activeCount":96},[],{"intervention":82,"totalTrials":122,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":426,"activeCount":96},[],{"trials":428,"activeCount":96},[],{"trials":430,"activeCount":96},[],{"trials":432,"activeCount":96},[],{"trials":434,"activeCount":96},[],{"trials":436,"activeCount":136,"soonestReadout":81},[437,453],{"nctId":438,"briefTitle":439,"status":440,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":447},"NCT03676257","Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases","COMPLETED",[],"2023-12-01","2008-01-01",20033,[446],"Metastatic Breast Cancer",[82,448,449,450,451,452],"Endocrine therapy","Combination of endocrine therapy and chemotherapy","Chemotherapy and targeted treatment","Combination of endocrine therapy and targeted treatment","Combination of chemotherapy, endocrine therapy and targeted treatment",{"nctId":79,"briefTitle":80,"status":113,"phases":454,"primaryCompletion":81,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},[],"2035-12-31","2010-01-01",150000,[27],[82,460,461],"Immunotherapeutic Agent","target treatment",{"intervention":72,"totalTrials":136,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":465,"activeCount":96},[],{"trials":467,"activeCount":96},[],{"trials":469,"activeCount":96},[],{"trials":471,"activeCount":96},[],{"trials":473,"activeCount":96},[],{"trials":475,"activeCount":136,"soonestReadout":71},[476],{"nctId":69,"briefTitle":70,"status":113,"phases":477,"primaryCompletion":71,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},[89],"2027-12-01","2020-09-04",332,[24,32],[72],{"intervention":460,"totalTrials":136,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":486,"activeCount":96},[],{"trials":488,"activeCount":96},[],{"trials":490,"activeCount":96},[],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":96},[],{"trials":496,"activeCount":136,"soonestReadout":81},[497],{"nctId":79,"briefTitle":80,"status":113,"phases":498,"primaryCompletion":81,"completion":455,"start":456,"enrollment":457,"conditions":499,"interventions":500},[],[27],[82,460,461],{"intervention":461,"totalTrials":136,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":504,"activeCount":96},[],{"trials":506,"activeCount":96},[],{"trials":508,"activeCount":96},[],{"trials":510,"activeCount":96},[],{"trials":512,"activeCount":96},[],{"trials":514,"activeCount":136,"soonestReadout":81},[515],{"nctId":79,"briefTitle":80,"status":113,"phases":516,"primaryCompletion":81,"completion":455,"start":456,"enrollment":457,"conditions":517,"interventions":518},[],[27],[82,460,461],{"intervention":520,"totalTrials":136,"cells":521},"Imatinib Mesylate 600 MG Oral",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":543,"NA":545},{"trials":523,"activeCount":96},[],{"trials":525,"activeCount":96},[],{"trials":527,"activeCount":96},[],{"trials":529,"activeCount":96},[530],{"nctId":531,"briefTitle":532,"status":533,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01827930","Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response","TERMINATED",[87],"2017-01-01","2009-07",68,[539],"Leukemia, Myeloid, Chronic-Phase",[520,541,542],"Imatinib Mesylate 400 MG Oral","Imatinib Mesylate",{"trials":544,"activeCount":96},[],{"trials":546,"activeCount":96},[],{"intervention":541,"totalTrials":136,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":561,"NA":563},{"trials":550,"activeCount":96},[],{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":96},[557],{"nctId":531,"briefTitle":532,"status":533,"phases":558,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":559,"interventions":560},[87],[539],[520,541,542],{"trials":562,"activeCount":96},[],{"trials":564,"activeCount":96},[],{"intervention":542,"totalTrials":136,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":579,"NA":581},{"trials":568,"activeCount":96},[],{"trials":570,"activeCount":96},[],{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":96},[575],{"nctId":531,"briefTitle":532,"status":533,"phases":576,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":577,"interventions":578},[87],[539],[520,541,542],{"trials":580,"activeCount":96},[],{"trials":582,"activeCount":96},[],{"intervention":584,"totalTrials":136,"cells":585},"Ketamine",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":606,"NA":608},{"trials":587,"activeCount":96},[],{"trials":589,"activeCount":96},[],{"trials":591,"activeCount":96},[],{"trials":593,"activeCount":96},[594],{"nctId":595,"briefTitle":596,"status":440,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":604},"NCT00210210","Administration of Ketamine to Prevent the Post-operative Pain",[87],"2005-07-31","2005-12-31","2004-01-31",230,[603,15],"Postoperative Pain",[584,605],"Saline solution",{"trials":607,"activeCount":96},[],{"trials":609,"activeCount":96},[],{"intervention":605,"totalTrials":136,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":624,"NA":626},{"trials":613,"activeCount":96},[],{"trials":615,"activeCount":96},[],{"trials":617,"activeCount":96},[],{"trials":619,"activeCount":96},[620],{"nctId":595,"briefTitle":596,"status":440,"phases":621,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":622,"interventions":623},[87],[603,15],[584,605],{"trials":625,"activeCount":96},[],{"trials":627,"activeCount":96},[],{"intervention":629,"totalTrials":122,"cells":630},"Efavirenz 600mg",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":650,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":632,"activeCount":96},[],{"trials":634,"activeCount":96},[635],{"nctId":636,"briefTitle":637,"status":440,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":646},"NCT01878890","Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.",[85],"2014-09-16","2016-12-31","2011-09-05",25,[644,645],"Solid Tumors","Non-Hodgkin's Lymphoma",[629,647,648,649],"Efavirenz 1200 mg","Efavirenz 1800 mg","Efavirenz 2200 mg",{"trials":651,"activeCount":96},[652],{"nctId":653,"briefTitle":654,"status":440,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":11,"conditions":658,"interventions":659},"NCT00964171","Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer",[86],"2010-07","2008-08",[293],[629],{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":96},[],{"trials":665,"activeCount":96},[],{"intervention":667,"totalTrials":122,"cells":668},"Cyclophosphamide",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":670,"activeCount":96},[],{"trials":672,"activeCount":96},[],{"trials":674,"activeCount":96},[675,690],{"nctId":676,"briefTitle":677,"status":678,"phases":679,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":686},"NCT02630368","A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","UNKNOWN",[85,86],"2023-05","2024-11","2015-09-18",197,[644,685,15],"Soft-tissue Sarcoma",[687,688,667,689],"Cyclophosphamide and JX-594 dose escalation","Cyclophosphamide and JX-594","Avelumab and JX-594 and Cyclophosphamide",{"nctId":691,"briefTitle":692,"status":440,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT00911183","Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable\u002FFrail Elderly. A Multicentric Randomized Phase II Trial",[86],"2012-12-31","2015-01-01","2008-12-02",67,[30],[700,701,702,703,704,705,706],"filgrastim","pegfilgrastim","rituximab","cyclophosphamide","liposome-encapsulated doxorubicin citrate","prednisone","vincristine sulfate",{"trials":708,"activeCount":96},[],{"trials":710,"activeCount":96},[],{"trials":712,"activeCount":96},[],{"intervention":714,"totalTrials":122,"cells":715},"fluorouracil",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":717,"activeCount":96},[],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":96},[722,735],{"nctId":723,"briefTitle":724,"status":533,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT00766142","Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer",[86],"2013-09-17","2007-05-01",18,[24,730],"Primary Peritoneal Cavity Cancer",[732,714,733,734],"cetuximab","leucovorin calcium","oxaliplatin",{"nctId":736,"briefTitle":737,"status":440,"phases":738,"primaryCompletion":739,"completion":740,"start":741,"enrollment":250,"conditions":742,"interventions":743},"NCT00467142","Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",[86],"2010-05","2011-12","2007-01-23",[24],[744,714,745,733,746],"bevacizumab","irinotecan hydrochloride","polymorphism analysis",{"trials":748,"activeCount":96},[],{"trials":750,"activeCount":96},[],{"trials":752,"activeCount":96},[],{"intervention":733,"totalTrials":122,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":756,"activeCount":96},[],{"trials":758,"activeCount":96},[],{"trials":760,"activeCount":96},[761,765],{"nctId":723,"briefTitle":724,"status":533,"phases":762,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":763,"interventions":764},[86],[24,730],[732,714,733,734],{"nctId":736,"briefTitle":737,"status":440,"phases":766,"primaryCompletion":739,"completion":740,"start":741,"enrollment":250,"conditions":767,"interventions":768},[86],[24],[744,714,745,733,746],{"trials":770,"activeCount":96},[],{"trials":772,"activeCount":96},[],{"trials":774,"activeCount":96},[],{"intervention":776,"totalTrials":136,"cells":777},"Association of Nivolumab + Relatlimab",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":779,"activeCount":96},[],{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[784],{"nctId":785,"briefTitle":786,"status":440,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":537,"conditions":791,"interventions":793},"NCT04095208","Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study",[86],"2024-09-29","2026-03-29","2020-02-27",[34,792],"Advanced Cancer",[776,794],"Nivolumab",{"trials":796,"activeCount":96},[],{"trials":798,"activeCount":96},[],{"trials":800,"activeCount":96},[],{"intervention":794,"totalTrials":136,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":804,"activeCount":96},[],{"trials":806,"activeCount":96},[],{"trials":808,"activeCount":96},[809],{"nctId":785,"briefTitle":786,"status":440,"phases":810,"primaryCompletion":788,"completion":789,"start":790,"enrollment":537,"conditions":811,"interventions":812},[86],[34,792],[776,794],{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"intervention":820,"totalTrials":136,"cells":821},"Acetaminophen",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":823,"activeCount":96},[],{"trials":825,"activeCount":96},[],{"trials":827,"activeCount":96},[828],{"nctId":829,"briefTitle":830,"status":440,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":840},"NCT00712712","Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer",[86],"2016-02-11","2016-03-16","2007-12-24",78,[837,838,839],"Metastatic Cancer","Pain","Unspecified Adult Solid Tumor, Protocol Specific",[820,841],"Morphine Sulfate",{"trials":843,"activeCount":96},[],{"trials":845,"activeCount":96},[],{"trials":847,"activeCount":96},[],{"intervention":841,"totalTrials":136,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":851,"activeCount":96},[],{"trials":853,"activeCount":96},[],{"trials":855,"activeCount":96},[856],{"nctId":829,"briefTitle":830,"status":440,"phases":857,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":858,"interventions":859},[86],[837,838,839],[820,841],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[],{"intervention":867,"totalTrials":136,"cells":868},"PD 0332991",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":870,"activeCount":96},[],{"trials":872,"activeCount":96},[],{"trials":874,"activeCount":96},[875],{"nctId":876,"briefTitle":877,"status":440,"phases":878,"primaryCompletion":879,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":885},"NCT01907607","Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib",[86],"2016-12","2019-02","2014-02",29,[884],"Advanced Gastrointestinal Stromal Tumors",[867],{"trials":887,"activeCount":96},[],{"trials":889,"activeCount":96},[],{"trials":891,"activeCount":96},[],{"intervention":893,"totalTrials":136,"cells":894},"plitidepsin",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":896,"activeCount":96},[],{"trials":898,"activeCount":96},[],{"trials":900,"activeCount":96},[901],{"nctId":902,"briefTitle":903,"status":533,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":16,"conditions":907,"interventions":909},"NCT01876043","Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed\u002FRefractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial",[86],"2015-04","2012-02",[908],"Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed\u002FRefractory Dedifferentiated Liposarcoma",[893],{"trials":911,"activeCount":96},[],{"trials":913,"activeCount":96},[],{"trials":915,"activeCount":96},[],{"intervention":917,"totalTrials":136,"cells":918},"Combination of MK3475 with Metronomic CP",{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":936,"PHASE4":938,"NA":940},{"trials":920,"activeCount":96},[],{"trials":922,"activeCount":96},[],{"trials":924,"activeCount":96},[925],{"nctId":926,"briefTitle":927,"status":440,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT02406781","Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial",[86],"2020-11-24","2023-01-15","2015-06",129,[27],[917,935],"Combination of MK3475 with Metronomic CP and G100",{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"intervention":935,"totalTrials":136,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[],{"trials":949,"activeCount":96},[950],{"nctId":926,"briefTitle":927,"status":440,"phases":951,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":952,"interventions":953},[86],[27],[917,935],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"trials":959,"activeCount":96},[],{"intervention":961,"totalTrials":136,"cells":962},"Association of berzosertib with gemcitabine",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":964,"activeCount":96},[],{"trials":966,"activeCount":96},[],{"trials":968,"activeCount":96},[969],{"nctId":970,"briefTitle":971,"status":440,"phases":972,"primaryCompletion":788,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT04807816","Targeting ATR in Soft-tissue Sarcomas",[86],"2026-04-21","2022-02-09",58,[977],"Leiomyosarcoma, Adult",[961,979],"Gemcitabine",{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"trials":985,"activeCount":96},[],{"intervention":979,"totalTrials":136,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[994],{"nctId":970,"briefTitle":971,"status":440,"phases":995,"primaryCompletion":788,"completion":973,"start":974,"enrollment":975,"conditions":996,"interventions":997},[86],[977],[961,979],{"trials":999,"activeCount":96},[],{"trials":1001,"activeCount":96},[],{"trials":1003,"activeCount":96},[],{"intervention":1005,"totalTrials":136,"cells":1006},"Temsirolimus",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1008,"activeCount":96},[],{"trials":1010,"activeCount":96},[],{"trials":1012,"activeCount":96},[1013],{"nctId":1014,"briefTitle":1015,"status":440,"phases":1016,"primaryCompletion":1017,"completion":879,"start":1018,"enrollment":1019,"conditions":1020,"interventions":1022},"NCT01827943","Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer",[86],"2014-12","2009-06",54,[1021],"Relapsed Bladder Cancer",[1005],{"trials":1024,"activeCount":96},[],{"trials":1026,"activeCount":96},[],{"trials":1028,"activeCount":96},[],{"intervention":1030,"totalTrials":136,"cells":1031},"Ezabenlimab + BI907828",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1033,"activeCount":96},[],{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[1038],{"nctId":1039,"briefTitle":1040,"status":1041,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":96,"conditions":1045,"interventions":1048},"NCT06084689","Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures","WITHDRAWN",[86],"2024-07-01","2024-06-14",[1046,32,297,24,1047],"Adult Soft Tissue Sarcoma","Biliary Tract Cancer",[1030],{"trials":1050,"activeCount":96},[],{"trials":1052,"activeCount":96},[],{"trials":1054,"activeCount":96},[],{"intervention":1056,"totalTrials":136,"cells":1057},"ICI treatment discontinuation",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1059,"activeCount":96},[],{"trials":1061,"activeCount":96},[],{"trials":1063,"activeCount":96},[1064],{"nctId":1065,"briefTitle":1066,"status":533,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1072},"NCT04880382","Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients",[86],"2026-02-23","2021-08-27",8,[32],[1056,1073],"ICI treatment continuation",{"trials":1075,"activeCount":96},[],{"trials":1077,"activeCount":96},[],{"trials":1079,"activeCount":96},[],{"intervention":1073,"totalTrials":136,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"trials":1087,"activeCount":96},[1088],{"nctId":1065,"briefTitle":1066,"status":533,"phases":1089,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1090,"interventions":1091},[86],[32],[1056,1073],{"trials":1093,"activeCount":96},[],{"trials":1095,"activeCount":96},[],{"trials":1097,"activeCount":96},[],{"intervention":687,"totalTrials":136,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":96},[],{"trials":1103,"activeCount":96},[],{"trials":1105,"activeCount":96},[1106],{"nctId":676,"briefTitle":677,"status":678,"phases":1107,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":1108,"interventions":1109},[85,86],[644,685,15],[687,688,667,689],{"trials":1111,"activeCount":96},[],{"trials":1113,"activeCount":96},[],{"trials":1115,"activeCount":96},[],{"intervention":688,"totalTrials":136,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1119,"activeCount":96},[],{"trials":1121,"activeCount":96},[],{"trials":1123,"activeCount":96},[1124],{"nctId":676,"briefTitle":677,"status":678,"phases":1125,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":1126,"interventions":1127},[85,86],[644,685,15],[687,688,667,689],{"trials":1129,"activeCount":96},[],{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"intervention":689,"totalTrials":136,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1137,"activeCount":96},[],{"trials":1139,"activeCount":96},[],{"trials":1141,"activeCount":96},[1142],{"nctId":676,"briefTitle":677,"status":678,"phases":1143,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":1144,"interventions":1145},[85,86],[644,685,15],[687,688,667,689],{"trials":1147,"activeCount":96},[],{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[],{"intervention":1153,"totalTrials":136,"cells":1154},"Glivec",{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1171,"PHASE4":1173,"NA":1175},{"trials":1156,"activeCount":96},[],{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[1161],{"nctId":1162,"briefTitle":1163,"status":533,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":11,"conditions":1168,"interventions":1170},"NCT00210119","Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response",[86],"2007-09","2009-03","2006-07-12",[1169],"Myeloid Leukemia, Chronic",[1153],{"trials":1172,"activeCount":96},[],{"trials":1174,"activeCount":96},[],{"trials":1176,"activeCount":96},[],{"intervention":734,"totalTrials":136,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1180,"activeCount":96},[],{"trials":1182,"activeCount":96},[],{"trials":1184,"activeCount":96},[1185],{"nctId":723,"briefTitle":724,"status":533,"phases":1186,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":1187,"interventions":1188},[86],[24,730],[732,714,733,734],{"trials":1190,"activeCount":96},[],{"trials":1192,"activeCount":96},[],{"trials":1194,"activeCount":96},[],{"intervention":1196,"totalTrials":136,"cells":1197},"anastrozole",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1199,"activeCount":96},[],{"trials":1201,"activeCount":96},[],{"trials":1203,"activeCount":96},[1204],{"nctId":1205,"briefTitle":1206,"status":440,"phases":1207,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT00871858","Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer",[86],"2013-11-30","2018-07-02","2008-03-18",120,[15],[1196,1214],"fulvestrant",{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[],{"trials":1220,"activeCount":96},[],{"intervention":1214,"totalTrials":136,"cells":1222},{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1224,"activeCount":96},[],{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":96},[1229],{"nctId":1205,"briefTitle":1206,"status":440,"phases":1230,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":1231,"interventions":1232},[86],[15],[1196,1214],{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[],{"trials":1238,"activeCount":96},[],{"intervention":1240,"totalTrials":136,"cells":1241},"efavirenz",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1243,"activeCount":96},[],{"trials":1245,"activeCount":96},[],{"trials":1247,"activeCount":96},[1248],{"nctId":1249,"briefTitle":1250,"status":440,"phases":1251,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT00964002","Efavirenz in Treating Patients With Metastatic Prostate Cancer",[86],"2011-09-19","2014-04-08","2008-05",61,[21],[1240],{"trials":1259,"activeCount":96},[],{"trials":1261,"activeCount":96},[],{"trials":1263,"activeCount":96},[],{"intervention":1265,"totalTrials":136,"cells":1266},"Phase 1: Trabectedin",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1268,"activeCount":96},[],{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[1273],{"nctId":1274,"briefTitle":1275,"status":440,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT02805725","Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide",[85,86],"2020-04","2021-12","2015-12",50,[1282],"Soft-tissue Sarcomas",[1265,1284,1285,1286],"Phase 2: Trabectedin","Phase 1: Cyclophosphamide","Phase 2: Cyclophosphamide",{"trials":1288,"activeCount":96},[],{"trials":1290,"activeCount":96},[],{"trials":1292,"activeCount":96},[],{"intervention":1284,"totalTrials":136,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":96},[],{"trials":1298,"activeCount":96},[],{"trials":1300,"activeCount":96},[1301],{"nctId":1274,"briefTitle":1275,"status":440,"phases":1302,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1303,"interventions":1304},[85,86],[1282],[1265,1284,1285,1286],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[],{"trials":1310,"activeCount":96},[],{"intervention":1285,"totalTrials":136,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[1319],{"nctId":1274,"briefTitle":1275,"status":440,"phases":1320,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1321,"interventions":1322},[85,86],[1282],[1265,1284,1285,1286],{"trials":1324,"activeCount":96},[],{"trials":1326,"activeCount":96},[],{"trials":1328,"activeCount":96},[],{"intervention":1286,"totalTrials":136,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":96},[],{"trials":1334,"activeCount":96},[],{"trials":1336,"activeCount":96},[1337],{"nctId":1274,"briefTitle":1275,"status":440,"phases":1338,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1339,"interventions":1340},[85,86],[1282],[1265,1284,1285,1286],{"trials":1342,"activeCount":96},[],{"trials":1344,"activeCount":96},[],{"trials":1346,"activeCount":96},[],{"intervention":1348,"totalTrials":136,"cells":1349},"Association of lurbinectedin and durvalumab",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1351,"activeCount":96},[],{"trials":1353,"activeCount":96},[],{"trials":1355,"activeCount":96},[1356],{"nctId":1357,"briefTitle":1358,"status":1041,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":96,"conditions":1362,"interventions":1366},"NCT05572476","Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer",[86],"2024-05-31","2023-10",[1363,1364,1365],"Small Cell Lung Cancer","Platinum-Sensitive Lung Small Cell Carcinoma","Extensive-stage Small-cell Lung Cancer",[1348,1367],"Association of carboplatin and etoposide",{"trials":1369,"activeCount":96},[],{"trials":1371,"activeCount":96},[],{"trials":1373,"activeCount":96},[],{"intervention":1367,"totalTrials":136,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1377,"activeCount":96},[],{"trials":1379,"activeCount":96},[],{"trials":1381,"activeCount":96},[1382],{"nctId":1357,"briefTitle":1358,"status":1041,"phases":1383,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":96,"conditions":1384,"interventions":1385},[86],[1363,1364,1365],[1348,1367],{"trials":1387,"activeCount":96},[],{"trials":1389,"activeCount":96},[],{"trials":1391,"activeCount":96},[],{"intervention":1393,"totalTrials":136,"cells":1394},"Phase 1 : Regorafenib",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1396,"activeCount":96},[],{"trials":1398,"activeCount":96},[],{"trials":1400,"activeCount":96},[1401],{"nctId":1402,"briefTitle":1403,"status":678,"phases":1404,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1421},"NCT03475953","A Phase I\u002FII Study of Regorafenib Plus Avelumab in Solid Tumors",[85,86],"2024-12-31","2025-12-31","2018-05-04",747,[1410,1411,1412,1047,1413,685,1414,1415,1416,292,1417,1418,297,1419,1420],"Colorectal Cancer Not MSI-H or MMR-deficient","GIST","Oesophageal or Gastric Carcinoma","Hepatocellular Carcinoma","Thyroid Cancer","Gastro-enteropancreatic Neuroendocrine Tumor","Non-small Cell Lung Cancer","Urothelial Carcinoma","HPV-Related Carcinoma","Renal Carcinoma","Mesotheliomas Pleural",[1393,1422,1423,1424,1425],"Phase 1 : Avelumab","Phase 2 : Regorafenib","Phase 2 : Avelumab","Phase 2: low-dose Regorafenib",{"trials":1427,"activeCount":96},[],{"trials":1429,"activeCount":96},[],{"trials":1431,"activeCount":96},[],{"intervention":1422,"totalTrials":136,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":96},[],{"trials":1437,"activeCount":96},[],{"trials":1439,"activeCount":96},[1440],{"nctId":1402,"briefTitle":1403,"status":678,"phases":1441,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1442,"interventions":1443},[85,86],[1410,1411,1412,1047,1413,685,1414,1415,1416,292,1417,1418,297,1419,1420],[1393,1422,1423,1424,1425],{"trials":1445,"activeCount":96},[],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":96},[],{"intervention":1423,"totalTrials":136,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":96},[],{"trials":1455,"activeCount":96},[],{"trials":1457,"activeCount":96},[1458],{"nctId":1402,"briefTitle":1403,"status":678,"phases":1459,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1460,"interventions":1461},[85,86],[1410,1411,1412,1047,1413,685,1414,1415,1416,292,1417,1418,297,1419,1420],[1393,1422,1423,1424,1425],{"trials":1463,"activeCount":96},[],{"trials":1465,"activeCount":96},[],{"trials":1467,"activeCount":96},[],{"intervention":1424,"totalTrials":136,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":96},[],{"trials":1473,"activeCount":96},[],{"trials":1475,"activeCount":96},[1476],{"nctId":1402,"briefTitle":1403,"status":678,"phases":1477,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1478,"interventions":1479},[85,86],[1410,1411,1412,1047,1413,685,1414,1415,1416,292,1417,1418,297,1419,1420],[1393,1422,1423,1424,1425],{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[],{"intervention":1425,"totalTrials":136,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1489,"activeCount":96},[],{"trials":1491,"activeCount":96},[],{"trials":1493,"activeCount":96},[1494],{"nctId":1402,"briefTitle":1403,"status":678,"phases":1495,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1496,"interventions":1497},[85,86],[1410,1411,1412,1047,1413,685,1414,1415,1416,292,1417,1418,297,1419,1420],[1393,1422,1423,1424,1425],{"trials":1499,"activeCount":96},[],{"trials":1501,"activeCount":96},[],{"trials":1503,"activeCount":96},[],{"intervention":700,"totalTrials":136,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1507,"activeCount":96},[],{"trials":1509,"activeCount":96},[],{"trials":1511,"activeCount":96},[1512],{"nctId":691,"briefTitle":692,"status":440,"phases":1513,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1514,"interventions":1515},[86],[30],[700,701,702,703,704,705,706],{"trials":1517,"activeCount":96},[],{"trials":1519,"activeCount":96},[],{"trials":1521,"activeCount":96},[],{"intervention":701,"totalTrials":136,"cells":1523},{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1525,"activeCount":96},[],{"trials":1527,"activeCount":96},[],{"trials":1529,"activeCount":96},[1530],{"nctId":691,"briefTitle":692,"status":440,"phases":1531,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1532,"interventions":1533},[86],[30],[700,701,702,703,704,705,706],{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[],{"trials":1539,"activeCount":96},[],{"intervention":702,"totalTrials":136,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1543,"activeCount":96},[],{"trials":1545,"activeCount":96},[],{"trials":1547,"activeCount":96},[1548],{"nctId":691,"briefTitle":692,"status":440,"phases":1549,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1550,"interventions":1551},[86],[30],[700,701,702,703,704,705,706],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[],{"trials":1557,"activeCount":96},[],{"intervention":704,"totalTrials":136,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":96},[],{"trials":1563,"activeCount":96},[],{"trials":1565,"activeCount":96},[1566],{"nctId":691,"briefTitle":692,"status":440,"phases":1567,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1568,"interventions":1569},[86],[30],[700,701,702,703,704,705,706],{"trials":1571,"activeCount":96},[],{"trials":1573,"activeCount":96},[],{"trials":1575,"activeCount":96},[],{"intervention":705,"totalTrials":136,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":96},[],{"trials":1581,"activeCount":96},[],{"trials":1583,"activeCount":96},[1584],{"nctId":691,"briefTitle":692,"status":440,"phases":1585,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1586,"interventions":1587},[86],[30],[700,701,702,703,704,705,706],{"trials":1589,"activeCount":96},[],{"trials":1591,"activeCount":96},[],{"trials":1593,"activeCount":96},[],{"intervention":706,"totalTrials":136,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":96},[],{"trials":1599,"activeCount":96},[],{"trials":1601,"activeCount":96},[1602],{"nctId":691,"briefTitle":692,"status":440,"phases":1603,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":1604,"interventions":1605},[86],[30],[700,701,702,703,704,705,706],{"trials":1607,"activeCount":96},[],{"trials":1609,"activeCount":96},[],{"trials":1611,"activeCount":96},[],{"intervention":1613,"totalTrials":136,"cells":1614},"PAZOPANIB treatment",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1616,"activeCount":96},[],{"trials":1618,"activeCount":96},[],{"trials":1620,"activeCount":96},[1621],{"nctId":1622,"briefTitle":1623,"status":440,"phases":1624,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT01876082","PAZOPANIB Efficacy and Tolerance in Desmoids Tumors",[86],"2018-03","2019-09","2012-09-18",72,[1630],"Progressive Desmoids Tumors",[1613,1632],"Active Comparator: Vinblastine and Methotrexate",{"trials":1634,"activeCount":96},[],{"trials":1636,"activeCount":96},[],{"trials":1638,"activeCount":96},[],{"intervention":1632,"totalTrials":136,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1651,"PHASE4":1653,"NA":1655},{"trials":1642,"activeCount":96},[],{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[1647],{"nctId":1622,"briefTitle":1623,"status":440,"phases":1648,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1649,"interventions":1650},[86],[1630],[1613,1632],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[],{"intervention":1658,"totalTrials":136,"cells":1659},"Irinotecan associated to fluorouracil and leucovorin",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1661,"activeCount":96},[],{"trials":1663,"activeCount":96},[],{"trials":1665,"activeCount":96},[1666],{"nctId":1667,"briefTitle":1668,"status":440,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT00210184","Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer",[86],"2009-04","2010-04","2004-07-21",42,[1675],"Gastric Cancer",[1658],{"trials":1678,"activeCount":96},[],{"trials":1680,"activeCount":96},[],{"trials":1682,"activeCount":96},[],{"intervention":744,"totalTrials":136,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1686,"activeCount":96},[],{"trials":1688,"activeCount":96},[],{"trials":1690,"activeCount":96},[1691],{"nctId":736,"briefTitle":737,"status":440,"phases":1692,"primaryCompletion":739,"completion":740,"start":741,"enrollment":250,"conditions":1693,"interventions":1694},[86],[24],[744,714,745,733,746],{"trials":1696,"activeCount":96},[],{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[],{"intervention":745,"totalTrials":136,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[1709],{"nctId":736,"briefTitle":737,"status":440,"phases":1710,"primaryCompletion":739,"completion":740,"start":741,"enrollment":250,"conditions":1711,"interventions":1712},[86],[24],[744,714,745,733,746],{"trials":1714,"activeCount":96},[],{"trials":1716,"activeCount":96},[],{"trials":1718,"activeCount":96},[],{"intervention":746,"totalTrials":136,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1722,"activeCount":96},[],{"trials":1724,"activeCount":96},[],{"trials":1726,"activeCount":96},[1727],{"nctId":736,"briefTitle":737,"status":440,"phases":1728,"primaryCompletion":739,"completion":740,"start":741,"enrollment":250,"conditions":1729,"interventions":1730},[86],[24],[744,714,745,733,746],{"trials":1732,"activeCount":96},[],{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[],{"intervention":1738,"totalTrials":136,"cells":1739},"Durvalumab",{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1741,"activeCount":96},[],{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[1746],{"nctId":1747,"briefTitle":1748,"status":440,"phases":1749,"primaryCompletion":1750,"completion":1751,"start":1752,"enrollment":1753,"conditions":1754,"interventions":1758},"NCT04705818","Combining Epigenetic And Immune Therapy to Beat Cancer.",[86],"2024-01-07","2025-07-17","2021-07-23",164,[397,1755,119,1756,1757],"Advanced Colorectal Carcinoma","Advanced Pancreatic Adenocarcinoma","Adult Solid Tumor",[1738,1759],"Tazemetostat",{"trials":1761,"activeCount":96},[],{"trials":1763,"activeCount":96},[],{"trials":1765,"activeCount":96},[],{"intervention":1759,"totalTrials":136,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1769,"activeCount":96},[],{"trials":1771,"activeCount":96},[],{"trials":1773,"activeCount":96},[1774],{"nctId":1747,"briefTitle":1748,"status":440,"phases":1775,"primaryCompletion":1750,"completion":1751,"start":1752,"enrollment":1753,"conditions":1776,"interventions":1777},[86],[397,1755,119,1756,1757],[1738,1759],{"trials":1779,"activeCount":96},[],{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"intervention":1785,"totalTrials":136,"cells":1786},"Ropivacaine",{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1788,"activeCount":96},[],{"trials":1790,"activeCount":96},[],{"trials":1792,"activeCount":96},[1793],{"nctId":1794,"briefTitle":1795,"status":440,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1802},"NCT00210132","Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery",[86],"2006-06-30","2008-02-28","2003-10-01",90,[603,18],[1785,1803],"Reference",{"trials":1805,"activeCount":96},[],{"trials":1807,"activeCount":96},[],{"trials":1809,"activeCount":96},[],{"intervention":1803,"totalTrials":136,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1813,"activeCount":96},[],{"trials":1815,"activeCount":96},[],{"trials":1817,"activeCount":96},[1818],{"nctId":1794,"briefTitle":1795,"status":440,"phases":1819,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1820,"interventions":1821},[86],[603,18],[1785,1803],{"trials":1823,"activeCount":96},[],{"trials":1825,"activeCount":96},[],{"trials":1827,"activeCount":96},[],{"intervention":1829,"totalTrials":136,"cells":1830},"Olaparib",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1845,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1832,"activeCount":96},[],{"trials":1834,"activeCount":96},[1835],{"nctId":1836,"briefTitle":1837,"status":440,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1844},"NCT02787642","A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced\u002FUnresectable Soft-tissue Sarcoma",[85],"2021-10","2022-05","2016-01",41,[685],[1829],{"trials":1846,"activeCount":96},[],{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[],{"intervention":1854,"totalTrials":136,"cells":1855},"Sirolimus combined with CP, MT and ZA",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1857,"activeCount":96},[],{"trials":1859,"activeCount":96},[1860],{"nctId":1861,"briefTitle":1862,"status":440,"phases":1863,"primaryCompletion":1864,"completion":1865,"start":1866,"enrollment":1867,"conditions":1868,"interventions":1870},"NCT02517918","Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma",[85],"2016-09-05","2021-11-16","2015-02",23,[1869,373],"Solid Tumor",[1854],{"trials":1872,"activeCount":96},[],{"trials":1874,"activeCount":96},[],{"trials":1876,"activeCount":96},[],{"trials":1878,"activeCount":96},[],{"intervention":1880,"totalTrials":136,"cells":1881},"Combination of trabectedin with durvalumab",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1898,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1883,"activeCount":96},[],{"trials":1885,"activeCount":96},[1886],{"nctId":1887,"briefTitle":1888,"status":440,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1897},"NCT03085225","Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.",[85],"2020-11-19","2022-01-04","2017-05-05",40,[1895,1896],"Ovarian Carcinoma","Soft Tissue Sarcoma",[1880],{"trials":1899,"activeCount":96},[],{"trials":1901,"activeCount":96},[],{"trials":1903,"activeCount":96},[],{"trials":1905,"activeCount":96},[],{"intervention":647,"totalTrials":136,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":96},[],{"trials":1911,"activeCount":96},[1912],{"nctId":636,"briefTitle":637,"status":440,"phases":1913,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":1914,"interventions":1915},[85],[644,645],[629,647,648,649],{"trials":1917,"activeCount":96},[],{"trials":1919,"activeCount":96},[],{"trials":1921,"activeCount":96},[],{"trials":1923,"activeCount":96},[],{"intervention":648,"totalTrials":136,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1934,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":96},[],{"trials":1929,"activeCount":96},[1930],{"nctId":636,"briefTitle":637,"status":440,"phases":1931,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":1932,"interventions":1933},[85],[644,645],[629,647,648,649],{"trials":1935,"activeCount":96},[],{"trials":1937,"activeCount":96},[],{"trials":1939,"activeCount":96},[],{"trials":1941,"activeCount":96},[],{"intervention":649,"totalTrials":136,"cells":1943},{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1945,"activeCount":96},[],{"trials":1947,"activeCount":96},[1948],{"nctId":636,"briefTitle":637,"status":440,"phases":1949,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":1950,"interventions":1951},[85],[644,645],[629,647,648,649],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"intervention":1961,"totalTrials":136,"cells":1962},"Nilotinib",{"EARLY_PHASE1":1963,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1964,"activeCount":96},[1965],{"nctId":1966,"briefTitle":1967,"status":1041,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":96,"conditions":1971,"interventions":1973},"NCT02774512","Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer",[84],"2017-11","2016-05",[1972],"Colon Cancer",[1961],{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[],{"trials":1981,"activeCount":96},[],{"trials":1983,"activeCount":96},[],{"intervention":732,"totalTrials":122,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1987,"activeCount":96},[],{"trials":1989,"activeCount":96},[],{"trials":1991,"activeCount":96},[1992],{"nctId":723,"briefTitle":724,"status":533,"phases":1993,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":1994,"interventions":1995},[86],[24,730],[732,714,733,734],{"trials":1997,"activeCount":96},[],{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[2002],{"nctId":2003,"briefTitle":2004,"status":440,"phases":2005,"primaryCompletion":2006,"completion":2007,"start":2008,"enrollment":2009,"conditions":2010,"interventions":2012},"NCT01827956","Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms",[],"2011-08","2013-12","2009-08",121,[2011],"Upper Gingival Squamous Cell Carcinoma",[2013],"Cetuximab",{"intervention":2015,"totalTrials":136,"cells":2016},"oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2018,"activeCount":96},[],{"trials":2020,"activeCount":96},[],{"trials":2022,"activeCount":96},[],{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"trials":2028,"activeCount":96},[2029],{"nctId":2030,"briefTitle":2031,"status":440,"phases":2032,"primaryCompletion":2033,"completion":2034,"start":2035,"enrollment":2036,"conditions":2037,"interventions":2039},"NCT03963544","Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)",[],"2024-09","2024-12","1990-01",492,[2038],"Gastro Intestinal Stromal Tumor",[2015],{"intervention":2041,"totalTrials":136,"cells":2042},"Neoadjuvant chemotherapy",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2044,"activeCount":96},[],{"trials":2046,"activeCount":96},[],{"trials":2048,"activeCount":96},[],{"trials":2050,"activeCount":96},[],{"trials":2052,"activeCount":96},[],{"trials":2054,"activeCount":96},[2055],{"nctId":2056,"briefTitle":2057,"status":440,"phases":2058,"primaryCompletion":2059,"completion":2059,"start":2060,"enrollment":2061,"conditions":2062,"interventions":2063},"NCT00462696","MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer",[89],"2008-12-31","2006-02",16,[15],[2041],{"intervention":2065,"totalTrials":136,"cells":2066},"Trabectedin",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2068,"activeCount":96},[],{"trials":2070,"activeCount":96},[],{"trials":2072,"activeCount":96},[],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[2079],{"nctId":2080,"briefTitle":2081,"status":440,"phases":2082,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":882,"conditions":2085,"interventions":2091},"NCT04008238","Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients",[89],"2024-08-31","2020-01-06",[34,374,2086,2087,2088,2089,2090],"Epithelioid Sarcoma","Solitary Fibrous Tumors","Hemangioendothelioma","Desmoplastic Round Cell Tumor","Synovial Sarcoma",[2065],{"intervention":448,"totalTrials":136,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2095,"activeCount":96},[],{"trials":2097,"activeCount":96},[],{"trials":2099,"activeCount":96},[],{"trials":2101,"activeCount":96},[],{"trials":2103,"activeCount":96},[],{"trials":2105,"activeCount":96},[2106],{"nctId":438,"briefTitle":439,"status":440,"phases":2107,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":2108,"interventions":2109},[],[446],[82,448,449,450,451,452],{"intervention":449,"totalTrials":136,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2113,"activeCount":96},[],{"trials":2115,"activeCount":96},[],{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[2124],{"nctId":438,"briefTitle":439,"status":440,"phases":2125,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":2126,"interventions":2127},[],[446],[82,448,449,450,451,452],{"intervention":450,"totalTrials":136,"cells":2129},{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2131,"activeCount":96},[],{"trials":2133,"activeCount":96},[],{"trials":2135,"activeCount":96},[],{"trials":2137,"activeCount":96},[],{"trials":2139,"activeCount":96},[],{"trials":2141,"activeCount":96},[2142],{"nctId":438,"briefTitle":439,"status":440,"phases":2143,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":2144,"interventions":2145},[],[446],[82,448,449,450,451,452],{"intervention":451,"totalTrials":136,"cells":2147},{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2149,"activeCount":96},[],{"trials":2151,"activeCount":96},[],{"trials":2153,"activeCount":96},[],{"trials":2155,"activeCount":96},[],{"trials":2157,"activeCount":96},[],{"trials":2159,"activeCount":96},[2160],{"nctId":438,"briefTitle":439,"status":440,"phases":2161,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":2162,"interventions":2163},[],[446],[82,448,449,450,451,452],{"intervention":452,"totalTrials":136,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2167,"activeCount":96},[],{"trials":2169,"activeCount":96},[],{"trials":2171,"activeCount":96},[],{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[],{"trials":2177,"activeCount":96},[2178],{"nctId":438,"briefTitle":439,"status":440,"phases":2179,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":2180,"interventions":2181},[],[446],[82,448,449,450,451,452],{"intervention":2183,"totalTrials":136,"cells":2184},"undefined",{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2186,"activeCount":96},[],{"trials":2188,"activeCount":96},[],{"trials":2190,"activeCount":96},[],{"trials":2192,"activeCount":96},[],{"trials":2194,"activeCount":96},[],{"trials":2196,"activeCount":96},[2197],{"nctId":2198,"briefTitle":2199,"status":440,"phases":2200,"primaryCompletion":535,"completion":535,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2204},"NCT02873923","Variability of Definitions for Survival Endpoints and Surrogate Properties for OS in Sarcoma Trials: a Meta-analysis",[],"2012-10",2846,[18],[2183],{"intervention":2206,"totalTrials":136,"cells":2207},"nivolumab monotherapy",{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2209,"activeCount":96},[],{"trials":2211,"activeCount":96},[],{"trials":2213,"activeCount":96},[],{"trials":2215,"activeCount":96},[],{"trials":2217,"activeCount":96},[],{"trials":2219,"activeCount":96},[2220],{"nctId":2221,"briefTitle":2222,"status":440,"phases":2223,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":2227,"interventions":2229},"NCT03963518","Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)",[],"2020-12","2017-01",631,[2228],"Cancer Treated With Immune-checkpoint Inhibitors",[2206,2230],"nivolumab plus ipilimumab",{"intervention":2230,"totalTrials":136,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2241,"NA":2243},{"trials":2234,"activeCount":96},[],{"trials":2236,"activeCount":96},[],{"trials":2238,"activeCount":96},[],{"trials":2240,"activeCount":96},[],{"trials":2242,"activeCount":96},[],{"trials":2244,"activeCount":96},[2245],{"nctId":2221,"briefTitle":2222,"status":440,"phases":2246,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":2247,"interventions":2248},[],[2228],[2206,2230]]